baCta Secures €7M to Reprogram Microorganisms for Industry
Paris-based biotech startup baCta has raised €7 million to advance its vision of transforming microorganisms into programmable molecular factories. The fresh funding will accelerate the company’s research platform, scale its bioprocess development, and prepare for early industrial partnerships in sectors ranging from pharmaceuticals to sustainable materials.
Engineering Living Molecular Factories
baCta operates at the intersection of synthetic biology, metabolic engineering, and industrial biomanufacturing. Its core technology focuses on redesigning microbial cells so they can be programmed to produce high-value molecules on demand — such as specialty chemicals, therapeutic precursors, and advanced biomaterials.
By treating cells as modular production units, the startup aims to replace traditional petrochemical and resource-intensive manufacturing with cleaner, biology-driven processes. Using advanced genome editing, AI-driven strain design, and automated high-throughput screening, baCta seeks to cut development timelines and improve yield, purity, and scalability.
Funding to Accelerate Biomanufacturing Roadmap
The €7 million round will be used to strengthen baCta‘s proprietary platform, expand its team of bioengineers and data scientists, and build pilot-scale capabilities for industrial testing. The company plans to prioritize applications where programmable microbes can deliver a clear cost and sustainability advantage, including green chemistry, biobased materials, and components for pharmaceutical and healthtech supply chains.
With regulators and major industries under pressure to decarbonize, demand for scalable bio-based production is rising. baCta positions its technology as a way to design and deploy new microbial strains much faster than legacy methods, enabling partners to explore multiple product candidates in parallel.
Paris as a Growing Synthetic Biology Hub
The funding also underscores Paris’s emergence as a European hotspot for deep tech and biotech innovation. By anchoring its R&D in France, baCta taps into a strong academic ecosystem, access to specialized talent, and growing investor interest in synthetic biology platforms that can serve multiple industries.
As programmable microorganisms move from the lab toward industrial deployment, startups like baCta are expected to play a central role in reshaping how complex molecules are designed, produced, and scaled globally.